Developing as a promising development in the battle against obesity, this medication is attracting considerable interest . This treatment combines effects of two recognized GLP-1 retatrutide peptide receptor agonists, dulaglutide , plus an unique glucose-dependent incretin component. Early patient data have indicated substantial weight loss in peo